Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMSCHL0)

• Drug Name: S-(Dimethylarsenic)Cysteine Drug Info
• Synonyms: [[(S)-2-Amino-2-carboxyethyl]thio]dimethylarsenic

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 46936846
  TTD Drug ID: DMSCHL0

Molecule-Related Drug Atlas

Drug(s) Targeting Nitric-oxide synthase endothelial (NOS3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tilarginine acetate	DMZBGI8	Myocardial infarction	BA41-BA43	Phase 3	[2]
L-NAME	DM01SR6	Hypertension	BA00-BA04	Phase 2	[3]
ACCLAIM	DM0FGDO	Angina pectoris	BA40	Phase 2	[4]
VAS-203	DMKU93J	Brain injury	NA07.Z	Phase 2	[5]
MTR105	DMT0K4F	Hypotension	BA20-BA21	Phase 2	[6]
Autologous cell based gene therapy	DMQA1VT	Pulmonary hypertension	BB01	Phase 1	[7]
L-NIL	DM6Y49D	N. A.	N. A.	Terminated	[8]
Acetate Ion	DMD08RH	Discovery agent	N.A.	Investigative	[1]
2-Methyl-2,4-Pentanediol	DMD45CU	Discovery agent	N.A.	Investigative	[1]
Heme	DMGC287	Discovery agent	N.A.	Investigative	[9]

Drug(s) Targeting Cytomegalovirus Protease (CMV UL80)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
US10071110, Compound cCDV	DM95YLX	N. A.	N. A.	Patented	[10]
C06909	DMJPW7C	N. A.	N. A.	Patented	[10]
Monoisopropyl Ester Phosphonic Acid Group	DMNJXHF	Discovery agent	N.A.	Investigative	[1]
N-(1-PHENYL-PROPYL)-FORMAMIDE	DMSHWYU	Discovery agent	N.A.	Investigative	[9]
O-Benzylsulfonyl-Serine	DMD25HJ	Discovery agent	N.A.	Investigative	[1]

Drug(s) Targeting Toll-like receptor 2 (TLR2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cadi-05	DMPTCYB	Prostate cancer	2C82.0	Phase 3	[11]
MCS-18	DMX4U0B	Autoimmune diabetes	5A10	Phase 2	[12]
OPN-305	DM1IBRT	Myelodysplastic syndrome	2A37	Phase 2	[13]
MALP-2S	DMBZ68C	Pancreatic cancer	2C10	Phase 1/2	[14]
Lipoteichoic acid	DMEMRW0	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[15]
OM-174	DM2THBX	Solid tumour/cancer	2A00-2F9Z	Phase 1	[16]
F-50040	DMMG6W5	Melanoma	2C30	Discontinued in Phase 1	[17]
CBLB-612	DMCFR8U	Radiation syndrome	NF00	Investigative	[18]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Cytomegalovirus Protease (CMV UL80)	TT5DOVB	SCAF_HCMVA	Inhibitor	[1]
Nitric-oxide synthase endothelial (NOS3)	TTCM4B3	NOS3_HUMAN	Inhibitor	[1]
Toll-like receptor 2 (TLR2)	TTY7ZHS	TLR2_HUMAN	Inhibitor	[1]

References

• [1] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [2] Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial. JAMA. 2007 Apr 18;297(15):1657-66.
• [3] Counter-regulation by atorvastatin of gene modulations induced by L-NAME hypertension is associated with vascular protection. Vascul Pharmacol. 2009 Oct;51(4):253-61.
• [4] CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008.
• [5] Nitric oxide synthase inhibition with the antipterin VAS203 improves outcome in moderate and severe traumatic brain injury: a placebo-controlled randomized Phase IIa trial (NOSTRA). J Neurotrauma. 2014 Oct 1;31(19):1599-606.
• [6] Nitric oxide synthase inhibitor (MTR-105) during open-heart surgery. A pilot double-blind placebo-controlled study of hemodynamic effects and safety. Cardiology. 2008;111(3):181-7.
• [7] Feasibility of using autologous transplantation to evaluate hematopoietic stem cell-based gene therapy strategies in transgenic mouse models of human disease. Mol Ther. 2002 Sep;6(3):422-8.
• [8] Discovery of a series of aminopiperidines as novel iNOS inhibitors. Bioorg Med Chem Lett. 2008 Jan 1;18(1):336-43.
• [9] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [10] Phosphonate compounds. US10071110.
• [11] Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology. 2012 August 1; 1(5): 699-716.
• [12] The novel arthritis-drug substance MCS-18 attenuates the antibody production in vivo. Acta Microbiol Immunol Hung. 2008 Mar;55(1):15-31.
• [13] Treatment with OPN-305, a humanized anti-Toll-Like receptor-2 antibody, reduces myocardial ischemia/reperfusion injury in pigs. Circ Cardiovasc Interv. 2012 Apr;5(2):279-87.
• [14] Failure of mycoplasma lipoprotein MALP-2 to induce NK cell activation through dendritic cell TLR2. Microbes Infect. 2011 Apr;13(4):350-8.
• [15] Lipoteichoic acid (LTA) of Streptococcus pneumoniae and Staphylococcus aureus activates immune cells via Toll-like receptor (TLR)-2, lipopolysaccha... J Biol Chem. 2003 May 2;278(18):15587-94.
• [16] Phase I study of OM-174, a lipid A analogue, with assessment of immunological response, in patients with refractory solid tumors. BMC Cancer. 2013 Apr 2;13:172.
• [17] Stability and CTL-activity of P40/ELA melanoma vaccine candidate. Biologicals. 2001 Sep-Dec;29(3-4):293-8.
• [18] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1752).